Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib – Patients With Metastatic Malignant Melanoma

Inclusion Criteria:

Patients with histological or cytological confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have or have not undergone prior chemotherapy for the treatment of melanoma
Measurable disease according to Response Criteria In Solid Tumors (RECIST)
Performance Status 0 - 1 according to ECOG (Eastern Cooperative Oncology Group) Performance Status
Age 18 years or more
Life expectancy > 3 months
Signed informed consent
Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this study
Male and female patients must use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last CP-4055 dose
Adequate haematological and biological functions

Exclusion Criteria:

Known brain metastases
Diagnosis of ocular malignant melanoma
Radiotherapy to more than 30 % of bone marrow
Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study

Requirement of concomitant treatment with a non-permitted medication:

Alternative drugs
High doses of vitamins
History of allergic reactions to ara-C or egg
History of allergic reactions attributed to compounds of similar chemical or biological composition to sorafenib
Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled inter-current illness including ongoing or active infection)
Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance
Pregnancy, breastfeeding or absence of adequate contraception for both male and female fertile patients
Known positive status for HIV and/or hepatitis B or C
Drug and/or alcohol abuse
Any reason why, in the investigator's opinion, the patient should not participate
Prior treatment with CP-4055 and/or sorafenib

Significant history of cardiac disease, including any of the following:

Uncontrolled hypertension
Unstable angina pectoris
Congestive heart failure
Myocardial infarction within the past 6 months
Unstable ventricular arrhythmia
Other cardiac arrhythmia
Condition that impairs ability to swallow pills
Tendency of bleeding